Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

s from these highly preventable surgical complications."

About XARELTO® (rivaroxaban tablets)

XARELTO® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. XARELTO® belongs to a group of medicines called anticoagulants. It works by blocking the blood clotting Factor Xa and thereby reduces the tendency of the blood to form clots. XARELTO® is the third New Drug Application the U.S. FDA has approved from the Janssen Pharmaceutical Companies this year.

Additionally, XARELTO® is being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. By the time of its completion, more than 65,000 patients will have participated in the rivaroxaban clinical development program. Rivaroxaban is being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.

Important Safety Information

WHAT IS XARELTO®?

XARELTO® (rivaroxaban tablets) is a prescription medicine used to help prevent blood clots from forming in patients after hip or knee replacement surgery.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

  • You should take XARELTO® exactly as directed by your doctor
  • Do not skip a dose or stop taking XARELTO® unless you are advised to do so by your doctor. Stopping may increase your risk of a blood clot
  • If a dose is missed, take XARELTO® as soon as possible and continue on the following day, taking XARELTO® as directed by your doctor. Do not take two doses at the same time
  • XARELTO® can cause b
    '/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the following conferences. , Deutsche Bank ... May 29, 2013 , Presentation time: 12:00 p.m. P.T. ... , Presentation date: Wednesday June 5, 2013 , Presentation ... A live webcast and 30-day archive of these presentations will ...
(Date:5/22/2013)... Mass. , May 22, 2013  Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... Mindray Medical International Limited (NYSE: MR ... medical devices worldwide, today announced the introduction of ... A Series portfolio. This is an anesthesia delivery ... and patient monitoring systems. The products will be ...
... (NYSE: SHP ) ("ShangPharma" or the "Company"), ... outsourcing company, today announced that Ms. Wenjuan Xiao, a ... has resigned from the board, effective October 13, 2011. ... is the mother of Michael Xin Hui, the chairman ...
Cached Medicine Technology:Mindray Announces Expansion of its A Series Anesthesia Portfolio 2
(Date:5/22/2013)... 22, 2013 Textile Exchange, a ... the textile industry, today released the 2011-12 Farm ... organic cotton production dropped 8% from last year. ... staggering 37% drop in 2010-11. Half of the ... The report, Textile Exchange’s seventh, provides unique data, ...
(Date:5/22/2013)... A new study published online today (Thursday) in the ... who visited fast food or chain restaurants in the U.S. ... likely to use calorie information given in the restaurants to ... eating at fast food or chain restaurants twice a week ... as those eating there once a week or less. , ...
(Date:5/22/2013)... Belleville, IL (PRWEB) May 22, 2013 ... of Veterans’ Appeals (BVA) in fiscal year 2012, with ... find themselves waiting longer for a decision as the ... to Allsup, which provides veterans disability appeal ... Department of Veterans Affairs. , Although the BVA received ...
(Date:5/22/2013)... People in the United States have been taking water ... much of the world, water shortages are normal and baths ... warns against taking water for granted and provides ways to ... in the United States. , Sharon Kleyne is host of ... live or by podcast on World Talk Radio, Voice America, ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
Breaking Medicine News(10 mins):Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 2Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 3Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 4Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2
... identify delay in key brain circuitry , WEDNESDAY, Feb. ... understanding of fragile X syndrome, which causes autism and ... , The researchers, whose findings are published in the ... developing insights into why some people with fragile X ...
... can happen to them , WEDNESDAY, Feb. 10 (HealthDay News) -- ... have fun, they just shouldn,t overlook their risk of HIV. ... up on a new campaign -- sponsored by MAC Cosmetics, nonprofit ... causes AIDS remains a potent threat to women as well. , ...
... , TRENTON, N.J. , Feb. ... that Patricia A. Barnett , a nurse and attorney with three ... Executive Officer of the Association by the Board of Directors. Barnett will ... Dr. Barbara Wright , who has been serving as interim CEO ...
... with type 2 diabetes who take a commonly prescribed class of ... for developing bone fractures. After taking a thiazolidinedione (TZD) for ... bone fracture than patients not taking TZDs, according to study results. ... are women older than 65. "Older women are already ...
... surgeons Clifford Buckley, M.D., and Ruth Bush, M.D., performed one ... GORE TAG Thoracic Endoprosthesis device for the treatment of a ... The goal of the trial is to gain insight ... (tear) as a less invasive alternative to major surgery. ...
... the world turns its sporting gaze towards Vancouver for ... Experimental Physiology marks the occasion with a special ... athletes must overcome to win gold. "When most ... images of snow and high mountains", said co-editor Mike ...
Cached Medicine News:Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 2Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 3Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 4Health News:Nurse-Attorney/Former Bristol-Myers Squibb Executive Selected To Lead New Jersey State Nurses Association 2Health News:Nurse-Attorney/Former Bristol-Myers Squibb Executive Selected To Lead New Jersey State Nurses Association 3Health News:Diabetes drug ups risk for bone fractures in older women 2Health News:Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury 2Health News:Exploring the limits: Understanding the challenges facing Winter Olympic champions 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: